Retinal Degenerative Diseases

Mechanisms and Experimental Therapy

  • John D. Ash
  • Christian Grimm
  • Joe G. Hollyfield
  • Robert E. Anderson
  • Matthew M. LaVail
  • Catherine Bowes Rickman

Part of the Advances in Experimental Medicine and Biology book series (volume 801)

Table of contents

  1. Front Matter
    Pages i-lxi
  2. Basic Processes: Development, Physiology and Function

    1. Front Matter
      Pages 1-1
    2. Evgenya Y. Popova, Colin J. Barnstable, Samuel Shao-Min Zhang
      Pages 3-8
    3. Barbara M. Braunger, Cora Demmer, Ernst R. Tamm
      Pages 9-13
    4. Xiaowu Gu, Alaina Reagan, Allen Yen, Faizah Bhatti, Alex W. Cohen, Michael H. Elliott
      Pages 15-21
    5. Alexander Aslanidis, Marcus Karlstetter, Yana Walczak, Herbert Jägle, Thomas Langmann
      Pages 31-41
    6. Saravanan Kolandaivelu, Visvanathan Ramamurthy
      Pages 43-48
    7. Cheryl M. Craft, Jing Huang, Daniel E. Possin, Anita Hendrickson
      Pages 49-56
    8. Xi-Qin Ding, Alexander Matveev, Anil Singh, Naoka Komori, Hiroyuki Matsumoto
      Pages 57-65
    9. Michael W. Stuck, Shannon M. Conley, Ryan A. Shaw, Roman Wolf, Muna I. Naash
      Pages 67-73
  3. Basic Processes: RPE

    1. Front Matter
      Pages 75-75
    2. Julian Esteve-Rudd, Vanda S. Lopes, Mei Jiang, David S. Williams
      Pages 85-90
    3. Lisa Shine, Claire Kilty, Jeffrey Gross, Breandan Kennedy
      Pages 97-103
    4. Olaf Strauß, Claudia Müller, Nadine Reichhart, Ernst R. Tamm, Nestor Mas Gomez
      Pages 113-119
  4. Basic Processes: Methodology

    1. Front Matter
      Pages 121-121
    2. Stephen P. Daiger, Sara J. Bowne, Lori S. Sullivan, Susan H. Blanton, George M. Weinstock, Daniel C. Koboldt et al.
      Pages 123-129

About these proceedings


This book will contain the proceedings of the XV International Symposium on Retinal Degeneration (RD2012).  A majority of those who will speak and present posters at the meeting will contribute to this volume.  The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70.  The RD Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them.  Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the “best” and “most important” meetings in the field.


The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy.


While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2010.  These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials.


The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general.  It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS.  Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2010 meeting and included in the proposed volume.  We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected in the volume.


Opthalmological nueroscience Retinal degeneration Vision

Editors and affiliations

  • John D. Ash
    • 1
  • Christian Grimm
    • 2
  • Joe G. Hollyfield
    • 3
  • Robert E. Anderson
    • 4
  • Matthew M. LaVail
    • 5
  • Catherine Bowes Rickman
    • 6
  1. 1.Department of OphthalmologyUniversity of FloridaGainesvilleUSA
  2. 2.University Hospital ZurichZurichSwitzerland
  3. 3.Cole Eye Institute at the Cleveland Clin Division of OphthalmologyClevelandUSA
  4. 4.Dean A. McGee Eye Inst.University of Oklahoma Health Science CenterOklahoma CityUSA
  5. 5.Beckman Vision CenterUniversity of California, San Francisco School of MedicineSan FranciscoUSA
  6. 6.Department of OphthalmologyDuke University Medical CenterDurhamUSA

Bibliographic information

  • DOI
  • Copyright Information Springer Science+Business Media, LLC 2014
  • Publisher Name Springer, New York, NY
  • eBook Packages Medicine
  • Print ISBN 978-1-4614-3208-1
  • Online ISBN 978-1-4614-3209-8
  • Series Print ISSN 0065-2598
  • Series Online ISSN 2214-8019
  • About this book
Industry Sectors